Biosensors CE marks BioMatrix Flex
This article was originally published in Clinica
Biosensors International has CE marked a new version of its BioMatrix drug-eluting stent (DES). Called BioMatrix Flex, the device incorporates Biosensors' abluminal biodegradable poly-lactic acid polymer, and the antirestenotic drug Biolimus A9. The DES will be launched "over the coming months", the firm said. Singapore-based Biosensors CE marked the first version of BioMatrix in January 2008, and the smaller-diameter (2.25mm) version in March 2009. The company has also gained French reimbursement approval for the first-generation form of BioMatrix. The stent will be available throughout France from January 28 to patients with coronary artery disease.